A Randomized Phase 2b Study of Surviving Vaccine Survaxm Plus Adjuvant Temozolomide For Newly-Diagnosed Glioblastoma (SURVIVE)

Publication Date

9-8-2023

Presented At:

EANO 2023 Annual Meeting

Content Type

Poster

Publisher's Site:

View at Publisher Website

Additional Authors:

Additional authors and institutional affiliations

This document is currently not available here.

Share

COinS